RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @sanoysalvoblog: No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
No hay evidencia de que objetivos de TA más bajos (≤135/85) de los estándar (≤140-160/90-100), en pacientes con HTA y enferrmedad cardiovascular, mejoren la mortalidad total, los eventos adversos graves o los eventos cardiovasculares totales Actualización
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneUK: "We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between pe…
RT @CochraneLibrary: Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertensi…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
RT @CochraneLibrary: Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertensi…
RT @CochraneLibrary: Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertensi…
Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertension and cardiovascular disease' https://t.co/iOLldoweKl #HTNEvidence #CochraneEvidence #hypertension https://t.co/ZIIs56xivH
“We found no evidence of a difference in total mortality, serious adverse events, or total cardiovascular events between people with hypertension and cardiovascular disease treated to a lower or to a standard blood pressure target” https://t.co/PSz21ui9rq
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @CochraneHTN: Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertension a…
Updated @cochranecollab review from @CochraneHTN - 'Blood pressure targets for the treatment of people with hypertension and cardiovascular disease' https://t.co/i68ucsndvJ #HTNEvidence #CochraneEvidence #hypertension https://t.co/PpBmz5x7ni
RT @SaludUmaza: Modificar(reducir) las umbrales de presion arterial no resulta en menor mortalidad y morbilidad para pacientes hipertensos.…
Modificar(reducir) las umbrales de presion arterial no resulta en menor mortalidad y morbilidad para pacientes hipertensos. @CochraneHTN https://t.co/3ISVQGlT3z
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @evidpediatria: Blood pressure targets for the treatment of people with hypertension and cardiovascular disease https://t.co/cTVvQ7aVBR…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @evidpediatria: Blood pressure targets for the treatment of people with hypertension and cardiovascular disease https://t.co/cTVvQ7aVBR…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
Top Noticias: Blood pressure targets for the treatment of people with hypertension and cardiovascular disease - Saiz - 2018 - The Cochrane Library - Wiley Online Library https://t.co/ZKrNk5Q6Al, see more https://t.co/PkUgzivC0z
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease https://t.co/cTVvQ7aVBR via @CochraneUK
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
Love this rant @hswapnil - #masterful #powerful #brilliant #youdaman 💪🏼💪🏼👏🏼🤟🏼🤜🏼🤜🏼🙌🏼🙌🏼this is worth 100-fold than any letter to the editor
RT @NuriaDeArgila: A @FerEsperanza y a mi nos gusta apoyarnos en la evidencia científica, gracias @jmmasencio 👇🏼 https://t.co/HCt84vKW9i
A @FerEsperanza y a mi nos gusta apoyarnos en la evidencia científica, gracias @jmmasencio 👇🏼
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
Great thread, tutorial & mike drop by @hswapnil!
RT @jmmasencio: No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLB…
No hay que afanarse tanto en bajar los límites de la HTA...mal que le.pese a la industria farmacéutica https://t.co/oDsDzLBcoq
Are lower blood pressure goals better than standard blood pressure goals for people with high blood pressure who also have heart or vascular problems? Read the latest Cochrane review here: https://t.co/xRM896ErJg https://t.co/1shgUCYkXL
RT @hswapnil: So the @CochraneHTN published this SR today https://t.co/bPwOrVpwar It suggests there is no advantage to lowering BP in patie…
RT @hswapnil: Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
RT @hswapnil: Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
RT @hswapnil: Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
@AKECassels @picardonhealth @CochraneHTN @Drug_Evidence @MedicineMatters @epaultaylor I suspect I won’t change @AKECassels mind since he doesn’t like (hates) SPRINT- but I hope @picardonhealth checks my critique https://t.co/okfE2h3Ydn If you believe &am
@AKECassels @picardonhealth @CochraneHTN @Drug_Evidence @MedicineMatters @epaultaylor In case you have an open mind, see https://t.co/okfE2gMnlP A 3 part breakdown of all the things wrong with this SR. I do SRs all the time. This raises huge red flags
RT @hswapnil: Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
@Ross_Tsuyuki @doreen_rabi Part 3 of the rant follows (ends coincidentally with exactly the point you are making!) https://t.co/okfE2h3Ydn
RT @hswapnil: Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
In part 1 we saw this SR only included a small subgroup of SPRINT And mixed DBP and MAP targeting trials https://t.co/kQngUMwRtS
Part 3 of the rant on this @CochraneHTN SR follows https://t.co/bPwOrVpwar
RT @hswapnil: Part 1 of the rantorial against @CochraneHTN SR is here https://t.co/kQngUMwRtS Where we saw that subgroups of apples & orang…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @Annette_LEXA: Aucun benefice net sur la sante d'une diminution de la PA a 135/85. On disait le contraire il y a peu de temps, non? Cela…
RT @dj_surfista: Atualmente, as evidências são insuficientes para justificar metas menores de pressão arterial (≤ 135/85 mmHg) em pessoas c…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @Annette_LEXA: Aucun benefice net sur la sante d'une diminution de la PA a 135/85. On disait le contraire il y a peu de temps, non? Cela…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
This @CochraneHTN review shows no added benefit of aiming for lower than standard BP targets in individuals with HTN and cardiovascular disease https://t.co/TySgSpJ1R5 @AKECassels
RT @JuanGrvas: Hypertension. The best available evidence does not support lower blood pressure goals over standard goals. Hipertensión. Coc…
Aucun benefice net sur la sante d'une diminution de la PA a 135/85. On disait le contraire il y a peu de temps, non? Cela devrait faire reflechir a plus d'humilité ceux qui utilisent la certitude et la references aux "etudes" pour se forger une opinion sci
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
Aucun benefice net sur la sante d'un diminution a la tension 135/85 . On disait le contraire il y a peu. Cela devrait faire reflechir certains avec plus d'humilité sur leurs certitudes...
Sin evidencia de los valores propuestos por AHA/ACC https://t.co/GUuZy7lEug
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @JuanGrvas: Hypertension. The best available evidence does not support lower blood pressure goals over standard goals. Hipertensión. Coc…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @AKECassels: The implications of this @CochraneHTN Review are huge: Millions of people are probably taking one, two or three antihypert…
RT @CochraneHTN: UPDATED #Cochrane review: insufficient evidence to justify lower than standard blood pressure targets in ppl w hypertensio…
RT @hswapnil: Part 1 of the rantorial against @CochraneHTN SR is here https://t.co/kQngUMwRtS Where we saw that subgroups of apples & orang…
Blood pressure guidelines have suggested that lower thresholds are required, but this review suggests no additional benefit. Are we truly practicing #evidencebasedmedicine? @bjparmenter
Atualmente, as evidências são insuficientes para justificar metas menores de pressão arterial (≤ 135/85 mmHg) em pessoas com #hipertensão e doença cardiovascular estabelecida. #bloodpressure #hypertension #enfarte #angina #stroke #cardiologia #cardiology h